Incidence, outcomes, and risk factors of pleural effusion in patients receiving dasatinib therapy for Philadelphia chromosome-positive leukemia

Dasatinib, a second-generation BCR-ABL1 tyrosine kinase inhibitor, is approved for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia, both as first-line therapy and after imatinib intolerance or resistance. While generally well tolerated, das...

وصف كامل

التفاصيل البيبلوغرافية

الحاوية / القاعدة:	Haematologica
المؤلفون الرئيسيون:	Timothy P. Hughes, Pierre Laneuville, Philippe Rousselot, David S. Snyder, Delphine Rea, Neil P. Shah, David Paar, Elisabetta Abruzzese, Andreas Hochhaus, Jeffrey H. Lipton, Jorge E. Cortes
التنسيق:	مقال
اللغة:	الإنجليزية
منشور في:	Ferrata Storti Foundation 2019-01-01
الوصول للمادة أونلاين:	https://haematologica.org/article/view/8745